| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -186,456 | -121,435 |
| Depreciation expense | 1,012 | 606 |
| Equity-based compensation expense | 34,347 | 22,470 |
| Amortization of discounts on marketable securities | 5,759 | 4,139 |
| Non-cash lease expense | 2,718 | 1,778 |
| Prepaid expenses and other current assets | 3,748 | 1,642 |
| Other non-current assets | 8,540 | 8,359 |
| Accounts payable | -695 | 4,607 |
| Operating lease liability | -2,977 | -1,985 |
| Accrued expenses | 5,337 | -2,407 |
| Net cash used in operating activities | -164,761 | -110,506 |
| Purchases of marketable securities | 253,212 | 145,580 |
| Maturities of marketable securities | 367,349 | 241,772 |
| Purchases of property and equipment | 5,085 | 5,085 |
| Net cash provided by (used in) investing activities | 109,052 | 91,107 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under the atm, net of issuance costs | 19,382 | - |
| Proceeds from exercise of options and employee stock purchase plan purchases | 2,158 | 1,802 |
| Net cash provided by financing activities | 21,540 | 1,802 |
| (decrease) increase in cash, cash equivalents and restricted cash | -34,169 | -17,597 |
| Cash and cash equivalents at beginning of period | 142,083 | - |
| Cash and cash equivalents at end of period | 107,914 | - |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)